Compare Stocks: GMTX, BMRN, MDGL, and HALO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRN BioMarin Pharmaceutical	$66.43 -0.8%	$62.43	$49.26 ▼ $70.98	$12.86B	0.24	2.07 million shs	1.48 million shs
GMTX Gemini Therapeutics	$80.05 +1.8%	$77.27	$1.16 ▼ $14.10	$3.47B	-0.12	189,291 shs	522,550 shs
HALO Halozyme Therapeutics	$110.76 +1.0%	$90.05	$61.22 ▼ $111.15	$12.57B	0.88	1.86 million shs	1.89 million shs
MDGL Madrigal Pharmaceuticals	$542.61 -0.8%	$529.33	$393.61 ▼ $615.00	$12.53B	-0.98	343,445 shs	143,452 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRN BioMarin Pharmaceutical	+3.29%	+2.07%	+11.64%	+18.59%	+13.34%
GMTX Gemini Therapeutics	+0.03%	-4.54%	+2.17%	+11.83%	+31.90%
HALO Halozyme Therapeutics	+1.80%	+2.43%	+33.29%	+53.16%	+49.52%
MDGL Madrigal Pharmaceuticals	+1.53%	+1.49%	+13.47%	+10.98%	+25.41%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRN BioMarin Pharmaceutical	$66.43 -0.8%	$62.43	$49.26 ▼ $70.98	$12.86B	0.24	2.07 million shs	1.48 million shs
GMTX Gemini Therapeutics	$80.05 +1.8%	$77.27	$1.16 ▼ $14.10	$3.47B	-0.12	189,291 shs	522,550 shs
HALO Halozyme Therapeutics	$110.76 +1.0%	$90.05	$61.22 ▼ $111.15	$12.57B	0.88	1.86 million shs	1.89 million shs
MDGL Madrigal Pharmaceuticals	$542.61 -0.8%	$529.33	$393.61 ▼ $615.00	$12.53B	-0.98	343,445 shs	143,452 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRN BioMarin Pharmaceutical	+3.29%	+2.07%	+11.64%	+18.59%	+13.34%
GMTX Gemini Therapeutics	+0.03%	-4.54%	+2.17%	+11.83%	+31.90%
HALO Halozyme Therapeutics	+1.80%	+2.43%	+33.29%	+53.16%	+49.52%
MDGL Madrigal Pharmaceuticals	+1.53%	+1.49%	+13.47%	+10.98%	+25.41%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMRN BioMarin Pharmaceutical	2.74	Moderate Buy	$89.17	34.24% Upside
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
HALO Halozyme Therapeutics	2.62	Moderate Buy	$91.20	-17.66% Downside
MDGL Madrigal Pharmaceuticals	2.78	Moderate Buy	$699.64	28.94% Upside

Current Analyst Ratings Breakdown

Latest GMTX, BMRN, MDGL, and HALO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2026	HALO Halozyme Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$115.00
9/1/2026	BMRN BioMarin Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$88.00 ➝ $90.00
8/31/2026	HALO Halozyme Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
8/31/2026	BMRN BioMarin Pharmaceutical	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$104.00 ➝ $105.00
8/31/2026	BMRN BioMarin Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$59.00 ➝ $60.00
8/26/2026	BMRN BioMarin Pharmaceutical	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$88.00
8/19/2026	BMRN BioMarin Pharmaceutical	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$98.00
8/18/2026	BMRN BioMarin Pharmaceutical	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/18/2026	BMRN BioMarin Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$60.00 ➝ $59.00
8/17/2026	BMRN BioMarin Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$82.00 ➝ $88.00
8/17/2026	BMRN BioMarin Pharmaceutical	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$105.00 ➝ $111.00

(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMRN BioMarin Pharmaceutical	$3.22B	3.99	$2.92 per share	22.73	$32.66 per share	2.03
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
HALO Halozyme Therapeutics	$1.40B	9.00	$4.91 per share	22.58	$1.26 per share	87.90
MDGL Madrigal Pharmaceuticals	$958.40M	13.08	N/A	N/A	$22.67 per share	23.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMRN BioMarin Pharmaceutical	$348.90M	$0.37	179.54	12.21	0.46	2.14%	5.32%	3.69%	10/26/2026 (Estimated)
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
HALO Halozyme Therapeutics	$316.89M	$3.35	33.06	11.99	0.43	24.86%	260.98%	23.91%	11/2/2026 (Estimated)
MDGL Madrigal Pharmaceuticals	-$288.28M	-$12.89	N/A	97.77	N/A	-25.32%	-56.65%	-25.53%	11/3/2026 (Estimated)

Latest GMTX, BMRN, MDGL, and HALO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	BMRN BioMarin Pharmaceutical	$0.95	$1.20	+$0.25	$0.23	$932.03 million	$989.71 million
8/6/2026	Q2 2026	HALO Halozyme Therapeutics	$1.79	$2.28	+$0.49	$1.90	$402.28 million	$481.00 million
7/30/2026	Q2 2026	MDGL Madrigal Pharmaceuticals	-$2.68	-$1.99	+$0.69	-$1.99	$352.13 million	$364.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMRN BioMarin Pharmaceutical	0.56	2.39	1.32
GMTX Gemini Therapeutics	N/A	71.49	71.49
HALO Halozyme Therapeutics	13.50	2.71	2.31
MDGL Madrigal Pharmaceuticals	0.65	3.20	2.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMRN BioMarin Pharmaceutical	98.71%
GMTX Gemini Therapeutics	75.42%
HALO Halozyme Therapeutics	97.79%
MDGL Madrigal Pharmaceuticals	98.50%

Insider Ownership

Company	Insider Ownership
BMRN BioMarin Pharmaceutical	0.68%
GMTX Gemini Therapeutics	12.90%
HALO Halozyme Therapeutics	2.50%
MDGL Madrigal Pharmaceuticals	17.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMRN BioMarin Pharmaceutical	3,221	193.57 million	192.26 million	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
HALO Halozyme Therapeutics	390	113.50 million	110.66 million	Optionable
MDGL Madrigal Pharmaceuticals	90	23.10 million	19.04 million	Optionable

GMTX, BMRN, MDGL, and HALO Headlines

Recent News About These Companies

Legal & General Group Plc Invests $6.63 Million in Madrigal Pharmaceuticals, Inc. $MDGL

September 3 at 4:40 AM | marketbeat.com

Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference

September 2 at 11:08 AM | markets.businessinsider.com

Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference

September 2 at 8:00 AM | globenewswire.com

Two Sigma Securities LLC Makes New Investment in Madrigal Pharmaceuticals, Inc. $MDGL

September 1 at 5:35 AM | marketbeat.com

The Manufacturers Life Insurance Company Invests $6.55 Million in Madrigal Pharmaceuticals, Inc. $MDGL

August 31 at 4:56 AM | marketbeat.com

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus Recommendation of "Moderate Buy" by Analysts

August 31 at 2:28 AM | americanbankingnews.com

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus Rating of "Moderate Buy" by Analysts

August 31 at 2:28 AM | marketbeat.com

Madrigal Pharmaceuticals, Inc. $MDGL Shares Bought by Wellington Management Group LLP

August 30, 2026 | marketbeat.com

Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by Algert Global LLC

August 30, 2026 | marketbeat.com

Hsbc Holdings PLC Makes New Investment in Madrigal Pharmaceuticals, Inc. $MDGL

August 29, 2026 | marketbeat.com

Canada Pension Plan Investment Board Takes Position in Madrigal Pharmaceuticals, Inc. $MDGL

August 29, 2026 | marketbeat.com

Bamco Inc. NY Makes New $2.42 Million Investment in Madrigal Pharmaceuticals, Inc. $MDGL

August 28, 2026 | marketbeat.com

Seven Fleet Capital Management LP Makes New $2.67 Billion Investment in Madrigal Pharmaceuticals, Inc. $MDGL

August 27, 2026 | marketbeat.com

Castleark Management LLC Buys New Stake in Madrigal Pharmaceuticals, Inc. $MDGL

August 27, 2026 | marketbeat.com

Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading Up 7.1% - Here's What Happened